Skip to content
Open menu Close menu

The Lymphocyte Genome Sensitivity (LGS) assay, or LGS test.

Published: Wed 13 Sept 2017
The Lymphocyte Genome Sensitivity (LGS) assay, or LGS test.

Professor Diana Anderson is working to develop a test for a range of cancers - now called CancerScan. She has provided a project update:

"Detection tests have been developed for many cancers, but there is no single test to identify cancer in general. We have developed such an assay.

In this modified Comet assay, we investigated peripheral lymphocytes of 208 individuals: 20 melanoma, 34 colon cancer, 4 lung cancer patients 18 suspect melanoma, 28 polyposis, 10 COPD patients and 94 healthy volunteers. The natural logarithm of the Olive tail moment was plotted for exposure to UVA through different agar depths for each of the above groups and analysed using a repeated measures regression model.

Response patterns for cancer patients formed a plateau after treating with UVA where intensity varied with different agar depths. In comparison, response patterns for healthy individuals returned towards control values and for pre/suspected cancers, were intermediate with less of a plateau. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic curves, of mean log Olive tail moments, for all cancers plus pre/suspected-cancer versus controls gave a value for the area under the curve of 0.87; for cancer versus pre/suspected-cancer plus controls the value was 0.89; and for cancer alone versus controls alone (excluding pre/suspected-cancer), the value was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable complementary measures.

Evidence presented indicates that this modified assay shows promise as both a stand-alone test and as a possible adjunct to other investigative procedures, as part of detection programmes for a range of cancers (Anderson et al, 2014 The FASEB Journal (2014) Vol 28, No 10 4563-4570)

A previously funded project was undertaken to develop instrumentation to automate the detection of cancer patients versus controls. This programme resulted in an unsuitable level of discrimination utilising the developed instrumentation, so the programme was terminated. Subsequently, Anderson et al are continuing to improve discrimination levels independently of this programme."

 

Share this

Upcoming events

View all events »